Performance of Diffusion and Perfusion MRI in Evaluating Primary Central Nervous System Lymphomas of Different Locations

CURRENT STATUS: UNDER REVIEW

BMC Medical Imaging  BMC Series

Zhen Xing
First Affiliated Hospital of Fujian Medical University

Nannan Kang
Zhongshan Hospital Xiamen University

Yu Lin
Zhongshan Hospital Xiamen University

Xiaofang Zhou
First Affiliated Hospital of Fujian Medical University

Zebin Xiao
Veterinary Medicine University of Pennsylvania

Dairong Cao
First Affiliated Hospital of Fujian Medical University

Corresponding Author
dairongcao@163.com
ORCiD: https://orcid.org/0000-0002-0051-3143

DOI:
10.21203/rs.2.19953/v2

SUBJECT AREAS
Nuclear Medicine & Medical Imaging

KEYWORDS
Primary central nervous system lymphomas, Diffusion, Perfusion
Abstract

**Background:** Diffusion and perfusion MRI can invasively define physical properties and angiogenic features of tumors, and guide the individual treatment. The purpose of this study was to investigate whether the diffusion and perfusion MRI parameters of primary central nervous system lymphomas (PCNSLs) are related to the tumor locations.

**Methods:** We retrospectively reviewed the diffusion, perfusion, and conventional MRI of 68 patients with PCNSLs at different locations (group 1: cortical gray matter, group 2: white matter, group 3: deep gray matter). Relative maximum cerebral blood volume (rCBV\textsubscript{max}) from perfusion MRI, minimum apparent diffusion coefficients (ADC\textsubscript{min}) from DWI of each group were calculated and compared by one-way ANOVA test. In addition, we compared the mean apparent diffusion coefficients (ADC\textsubscript{mean}) in three different regions of control group.

**Results:** The rCBV\textsubscript{max} of PCNSLs yielded the lowest value in the white matter group, and the highest value in the cortical gray matter group ($P < 0.001$). However, the ADC\textsubscript{min} of each subgroup was not statistically different. The ADC\textsubscript{mean} of each subgroup in control group was not statistically different.

**Conclusion:** Our study confirms that rCBV\textsubscript{max} of PCNSLs are related to the tumor location, and provide simple but effective information for guiding the clinical practice of PCNSLs.

**Background**

Primary central nervous lymphomas (PCNSLs) are malignant tumors with increased incidence rates [1]. To date, methotrexate-based chemotherapy is the cornerstone for PCNSLs treatment. The response to initial high-dose chemotherapy is a reliable indicator of the patients’ long-term survival [2-5]. As proposed by a previous study, the chemotherapy response is predominantly determined by the delivery of drugs through the vascular system [6]. Besides, some researchers have documented that PCNSLs with different cellular growth patterns may have different prognoses [7, 8]. Diffusion-weighted imaging (DWI) can assess the Brownian movement of water in the microscopic tissue environment by using apparent diffusion coefficient (ADC) values. Densely packed tumor cells with a high nuclear-to-cytoplasmic ratio could reduce water molecule motion [9, 10]. Few studies have suggested a significant correlation between ADC values and prognosis of patients with PCNSLs.
treated with methotrexate[11-13].

Dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) can provide physiological information about vascular endothelial proliferation and angiogenesis [14-17]. Since tumor aggressiveness correlates with neovascularization, DSC-PWI is useful in the preoperative evaluation of brain tumors (including PCNSLs)[13-15,11]. Regional CBV (rCBV) derived from DSC-PWI can provide important hemodynamic information by intravenous injection of gadolinium-based contrast agent [18-20]. The response to chemotherapy is mainly determined by the delivery of drugs to the tumor through the vascular system [6]. Therefore, the rCBV value might be used as a biomarker of treatment responses in PCNSLs.

From the imaging perspective, diffusion and perfusion MRI may be helpful for a comprehensive assessment of the cellularity and vascularity, and a prediction of treatment response of PCNSLs. To our knowledge, there is no study in the literature combining diffusion and perfusion techniques to evaluate the PCNSLs of different locations. Therefore, our research aims to investigate whether DWI and DSC-PWI parameters are correlated with tumor locations, and provide evidence for clinical decision-making and prognostic evaluation.

**Methods**

**Patients**

The institutional review board of our hospital approved this study and informed consent was waived due to the retrospective design. Our institution’s database identified 166 patients who underwent MR examination for potential PCNSLs between October 2009 and September 2017. The inclusion criteria were as follow: (a) immunocompetent patients, (b) histopathological diagnosis of PCNSLs, (c) available pretreatment conventional MRI (cMRI), DWI and DSC-PWI. Patients with poor image quality were excluded. Ultimately, 68 patients (31 males and 37 females, age range 29-78 years; mean age 56.80 years) were included.

**MR Imaging Techniques**

All MR images were acquired in the routine clinical workup using a 3.0 Tesla MRI system (Magnetom Verio TIM; Siemens Healthcare, Erlangen, Germany) with an eight-channel head coil. The cMRI
protocols consisted of axial T1WI (TR/TE, 250 /2.48 ms), axial T2WI (TR/TE, 4000 /96 ms), axial FLAIR (TR, 9000 ms; TE, 94 ms; TI, 2500 ms), and contrast-enhanced T1WI (CE-T1WI; TR/TE, 250 ms/2.48 ms) in 3 orthogonal planes. It was uniform in all series about FOV 220×220 mm, section thickness 5 mm, and intersection gap 1.0 mm.

DWI was performed in the axial plane with a spin-echo-planar sequence (TR/TE, 8200/102ms; NEX, 2.0; b-values, 0 and 1000 s/mm2). Corresponding ADC maps were generated automatically by the MRI system.

DSC-PWI was achieved with a gradient-recalled T2*-weighted echo-planar imaging sequence (TR/TE, 1000–1250/54 ms; NEX, 1.0; flip angle, 35°). In the first three phases, non-enhanced images were scanned to establish a pre-contrast baseline. When the scan was to the fourth phase of DSC-PWI, a standard dose of 0.1 mmol/kg of gadobente dimeglumine (Gd-BOPTA) was injected intravenously with a flow rate of 3 ml/s, followed by a 20ml continuous saline flush.

**Data Processing**

All imaging assessments were performed on a Siemens workstation with standard software. All cMRI data concerning notch sign and contrast-enhancement pattern were assessed by two neuroradiologists who were blinded to tumor histology. When two observers disagreed, a senior neuroradiologist made the final decision.

To assess DWI data, ADC values were measured by manually placing ROIs on the ADC maps. At least five small round ROIs (25–40mm²) were selected inside the tumor areas of visually lowest ADC. The ROI placements were made from the enhancing solid portion of the lesion, avoiding necrotic, cystic, hemorrhagic, or visible blood vessel that might affect the ADC values. For each patient, the enhancing solid portion of the tumor was identified on T2WI and CE-T1WI. Finally, the minimum ADC (ADC\textsubscript{min}) was calculated from the ROI with the lowest ADC value. The mean ADC (ADC\textsubscript{mean}) values of normal cortical gray matter (CGM), white matter (WM) and deep gray matter (DGM) were also calculated.

ADC values were expressed as ×10\(^3\)mm\(^2\)/s.

To evaluate DSC-PWI data, whole-brain CBV maps were generated using a single-compartment model.
The relative maximum CBV value (rCBV_{max}) was calculated by dividing the maximum CBV value of the tumor by the mean CBV value of the contralateral unaffected white matter. Therefore, the rCBV value was used as a quantitative parameter without unit. To minimize variances in rCBV_{max} values in each patient, measurements of rCBV_{max} values were performed with the same ROIs as those used for ADC measurement.

All the parameters derived from DWI and DSC-PWI were measured by a neuroradiologist (Z.X. with 9 years of experience in brain imaging) who blinded to the tumor histology.

**Statistical Analysis**

All quantitative parameters are presented as the means ± standard deviation (SD). A one-way ANOVA test was performed for the ADC_{min}, ADC_{mean} and rCBV_{max} values with a Least Significant Difference (LSD) among groups. All P-values <0.05 were considered to represent statistical significance.

Statistical analysis was performed using SPSS software (Version 22.0, SPSS Inc., Chicago, USA) and MedCalc (Version 12.1.0, MedCalc Inc., Mariakierke, Belgium).

**Results**

There was a total of 68 patients with 95 lesions. Totally 73 lesions (single lesion in 36 cases and multiple lesions in 17 cases) underwent DSC-PWI and 82 lesions (single lesion in 37 cases and multiple lesions in 23 cases) underwent DWI. The clinical and cMRI characteristics were summarized in Table 1. Homogenous contrast-enhancement pattern and notch sign were non-specific observed in PCNSLs regardless of location.

Table 2 and Fig.1 showed the results of rCBV_{max}, ADC_{mean} and ADC_{min} for the three groups. A significant difference of rCBV_{max} was found among the three locations (P < 0.001). As shown in Fig.1-4, the rCBV_{max} values were lowest in WM and highest in CGM. However, ADC_{min} values of subgroup tumors were not significantly different (Fig. 1). In addition, ADC_{mean} values of subgroup of the normal control were not significantly different (Fig. 1).

**Discussion**

In our study, we present the evidence that rCBV_{max} values of PCNSLs are related to their locations.
The CGM PCNSLs have the highest rCBV_{max}, and the WM tumors have the lowest rCBV_{max}. However, there were no significant differences among ADC_{min} values of PCNSLs with different locations.

The role of cMRI in the characterization of PCNSLs has been well established [21]. However, the cMRI features of PCNSLs (homogenous contrast-enhancement pattern and notch sign) at various sites are non-specific.

ADC_{min} values have been extensively used to investigate PCNSL and its prognosis[13, 22, 23].

Previous studies have shown a significant inverse correlation between tumor cell density and ADC value in PCNSLs, suggesting ADC to be a surrogate marker for tumor proliferation and Ki-67 index[23-25]. Barajas et al [11] reported that ADC measurements could predict clinical prognosis in patients with PCNSLs. The study indicated that lower ADC_{25%} and ADC_{min} values were predictive of shorter progression-free survival (PFS) and overall survival (OS). Similarly, Valles et al [26] found that both mean and minimum ADC values of PCNSLs have strong correlations with patients’ PFS and OS.

However, as shown by Schob et al, proliferative activity revealed by ADC was not related to the location of PCNSLs[23]. In accordance with the previous study, our research demonstrated no correlations between ADC_{min} and the locations of PCNSLs. Meanwhile, our research also confirmed that there was no differences in ADC_{mean} values between different locations of control group.

Therefore, it is conceivable that DWI variables may not be varied among PCNSLs with different locations.

DSC-PWI has the potential to provide hemodynamic information about PCNSLs [27-30]. In healthy subjects, the CGM structures have the highest blood volume, followed by DGM and WM [31]. PCNSLs represent unique angiocentric growth patterns, but lack abundant neoangiogenesis [1, 32, 33]. Thus, we can infer that the PCNSLs of CGM have the highest rCBV, followed by DGM and WM tumors. Our findings are in good agreement with such a theoretical hypothesis. PCNSLs are usually treated by high-dose methotrexate or radiation therapy [5, 34]. The response to initial methotrexate therapy is significantly associated with patient’s prognosis [35]. Clinicians could adjust the drug dose and initiate individualized second-line salvage therapies in chemotherapy-resistant patients, which may
minimize neurological toxicity and improve prognosis [36]. It is commonly acknowledged that the delivery of the drug through the vascular system determines the response to chemotherapy [6]. Notably, Valles et al [26] reported that rCBV value could be a valid imaging biomarker of clinical outcome: patients of PCNSLs with lower tumor rCBV values at pre-therapy baseline have significantly shorter PFS and OS compared with the control group. Therefore, we can also postulate that PCNSLs of CGM have the best chemotherapeutic response and clinical prognosis, followed by DWM and WM tumors. Location of PCNSLs could stratifies the patients into different risk groups to guide the methotrexate-based chemotherapy.

There are some potential limitations in our study. First, we did not verify the clinical prognostic factors of PCNSLs, although Valles et al. [26] confirmed that tumor rCBV values might be biomarkers of treatment response. A multicentered prospective investigation with long-term follow-up should be further studied to verify our speculation. Second, this retrospective study may lead to some biases in the case selection. Therefore, more extensive trials are needed to validate and establish expected datasets to refine current scores and establish new risk factors. Third, due to the lack of available tumor-tissue samples, we were unable to establish a point to point rCBV$_{\text{max}}$ measurements associated with histopathological characteristics.

Conclusions
Our study confirms that the cerebral blood supplies of the PCNSLs are related to their locations. We present the first evidence of tumor location as a simple but effective prognostic indicator of PCNSLs. The PCNSLs of CGM may have the best prognosis, whereas tumors of WM may have the worst prognosis.

Declarations

Ethics approval and consent to participate
This work has been carried out with ethics approval from the Fujian Medical University. The need for patient consent was waived.

Consent for publication
Not applicable
**Availability of data and material**

Due to statutory provisions regarding data and privacy protection, the dataset supporting the conclusions of this article is available upon individual request directed to the corresponding author.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This study was funded by the funding project of medical innovation of Fujian Province (No. 2019-CX-23) and the joint project of health and education of Fujian Province (No. 2019-WJ-10). These funders provide necessary materials such as ear plugs in the acquisition of MR images and possible fees for open access publication.

**Authors' contributions**

Z.X. analyzed and interpreted the patients’ data regarding Primary central nervous system lymphomas and was a major contributor in writing the manuscript. N.K. participated in the design of the study, performed the statistical analysis. D.C. participated in the design of the study, performed the experiments and the statistical analysis. Y.L. participated in the design of the study and assisted with manuscript preparation. X.Z. participated in the design of the study. Z.X. assisted with manuscript preparation. All authors have read and approved the final manuscript.

**Acknowledgements**

Not applicable

**Abbreviations**

MRI: Magnetic resonance imaging; PCNSLs: Primary central nervous system lymphomas; \( r\text{CBV}_{\text{max}} \): Relative maximum cerebral blood volume; \( r\text{CBV} \): Relative cerebral blood volume; CBV: Cerebral blood volume; \( \text{ADC}_{\text{min}} \): Minimum apparent diffusion coefficients; DWI: Diffusion weighted imaging; \( \text{ADC}_{\text{mean}} \): Mean apparent diffusion coefficients; ADC: Apparent diffusion coefficients; DSC-PWI: Dynamic susceptibility contrast perfusion-weighted imaging; Cmri: Conventional magnetic resonance imaging; T1WI: T1 weighted imaging; T2WI: T2 weighted imaging; FLAIR: Fluid attenuated inversion recovery; TR: repetition time; TE: Echo time; TI: Inversion time; CE-T1WI: Contrast-enhanced T1 weighted
imaging; Gd-BOPTA: gadobente dimeglumine; FOV: Field of view; NEX: Number of excitation; ROI: Region of interest; CGM: Cortical gray matter; WM: White matter; DGM: Deep gray matter; SD: Standard deviation; LSD: Least Significant Difference; OS: Overall survival; PFS: Progression-free survival.

References

1. Koeller KK, Smirniotopoulos JG, Jones RV: Primary central nervous system lymphoma: radiologic-pathologic correlation. Radiographics : a review publication of the Radiological Society of North America, Inc 1997, 17(6):1497-1526.

2. McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000, 46(1):51-60; discussion 60-51.

3. Momota H, Narita Y, Maeshima AM, Miyakita Y, Shinomiya A, Maruyama T, Muragaki Y, Shibui S: Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma. Journal of neuro-oncology 2010, 98(3):341-348.

4. Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, Grossman SA, Ye X: High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology 2014, 83(3):235-239.

5. Kansara R, Shenkier TN, Connors JM, Sehn LH, Savage KJ, Gerrie AS, Villa D: Rituximab with high-dose methotrexate in primary central nervous system lymphoma. American journal of hematology 2015, 90(12):1149-1154.

6. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK: Normalization of the vasculature for treatment of cancer and other diseases. Physiological reviews 2011, 91(3):1071-1121.
7. Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M et al: Gene expression and angiotropism in primary CNS lymphoma. *Blood* 2006, **107**(9):3716-3723.

8. Rubenstein JL, Shen A, Batchelor TT, Kadoch C, Treseler P, Shuman MA: Differential gene expression in central nervous system lymphoma. *Blood* 2009, **113**(1):266-267; author reply 267-268.

9. Kang Y, Choi SH, Kim YJ, Kim KG, Sohn CH, Kim JH, Yun TJ, Chang KH: Gliomas: Histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging--correlation with tumor grade. *Radiology* 2011, **261**(3):882-890.

10. Yan R, Haopeng P, Xiaoyuan F, Jinsong W, Jiawen Z, Chengjun Y, Tianming Q, Ji X, Mao S, Yueyue D et al: Non-Gaussian diffusion MR imaging of glioma: comparisons of multiple diffusion parameters and correlation with histologic grade and MIB-1 (Ki-67 labeling) index. *Neuroradiology* 2016, **58**(2):121-132.

11. Barajas RF, Jr., Rubenstein JL, Chang JS, Hwang J, Cha S: Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. *AJNR American journal of neuroradiology* 2010, **31**(1):60-66.

12. Zhang Y, Zhang Q, Wang XX, Deng XF, Zhu YZ: Value of pretherapeutic DWI in evaluating prognosis and therapeutic effect in immunocompetent patients with primary central nervous system lymphoma given high-dose methotrexate-based chemotherapy: ADC-based assessment. *Clin Radiol* 2016, **71**(10):1018-1029.

13. Huang WY, Wen JB, Wu G, Yin B, Li JJ, Geng DY: Diffusion-Weighted Imaging for Predicting and Monitoring Primary Central Nervous System Lymphoma
Treatment Response. *AJNR Am J Neuroradiol* 2016, 37(11):2010-2018.

14. Nagesh V, Chenevert TL, Tsien CI, Ross BD, Lawrence TS, Junck L, Cao Y: 
Quantitative characterization of hemodynamic properties and vasculature
dysfunction of high-grade gliomas. *NMR in biomedicine* 2007, 20(6):566-577.

15. Seeger A, Braun C, Skardelly M, Paulsen F, Schittenhelm J, Ernemann U, Bisdas S: 
Comparison of three different MR perfusion techniques and MR spectroscopy
for multiparametric assessment in distinguishing recurrent high-grade
gliomas from stable disease. *Academic radiology* 2013, 20(12):1557-1565.

16. Barajas RF, Jr., Phillips JJ, Vandenberg SR, McDermott MW, Berger MS, Dillon WP, Cha 
S: Pro-angiogenic cellular and genomic expression patterns within
glioblastoma influences dynamic susceptibility weighted perfusion MRI. 
*Clinical radiology* 2015, 70(10):1087-1095.

17. Cha S: Perfusion MR imaging: basic principles and clinical applications.
*Magnetic resonance imaging clinics of North America* 2003, 11(3):403-413.

18. Bjornerud A, Sorensen AG, Mouridsen K, Emblem KE: T1- and T2*-dominant 
evacasation correction in DSC-MRI: part I--theoretical considerations and 
implications for assessment of tumor hemodynamic properties. *Journal of cerebrovascular and cerebral metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism* 2011, 31(10):2041-2053.

19. Ginat DT, Mangla R, Yeaney G, Schaefer PW, Wang H: Correlation between
dynamic contrast-enhanced perfusion MRI relative cerebral blood volume
and vascular endothelial growth factor expression in meningiomas. *Academic radiology* 2012, 19(8):986-990.

20. Ho CY, Cardinal JS, Kamer AP, Kralik SF: Relative cerebral blood volume from
dynamic susceptibility contrast perfusion in the grading of pediatric primary
21. Zhang D, Hu LB, Henning TD, Ravarani EM, Zou LG, Feng XY, Wang WX, Wen L: MRI findings of primary CNS lymphoma in 26 immunocompetent patients. *Korean journal of radiology* 2010, **11**(3):269-277.

22. Lu SS, Kim SJ, Kim N, Kim HS, Choi CG, Lim YM: Histogram analysis of apparent diffusion coefficient maps for differentiating primary CNS lymphomas from tumefactive demyelinating lesions. *AJR Am J Roentgenol* 2015, **204**(4):827-834.

23. Schob S, Meyer J, Gawlitza M, Frydrychowicz C, Müller W, Preuss M, Bure L, Quäschling U, Hoffmann KT, Surov A: Diffusion-Weighted MRI Reflects Proliferative Activity in Primary CNS Lymphoma. *PLoS One* 2016, **11**(8):e0161386.

24. Surov A, Gottschling S, Mawrin C, Prell J, Spielmann RP, Wienke A, Fiedler E: Diffusion-Weighted Imaging in Meningioma: Prediction of Tumor Grade and Association with Histopathological Parameters. *Transl Oncol* 2015, **8**(6):517-523.

25. Schob S, Meyer HJ, Dieckow J, Pervinder B, Pazaitis N, Höhn AK, Garnov N, Horvath-Rizea D, Hoffmann KT, Surov A: Histogram Analysis of Diffusion Weighted Imaging at 3T is Useful for Prediction of Lymphatic Metastatic Spread, Proliferative Activity, and Cellularity in Thyroid Cancer. *Int J Mol Sci* 2017, **18**(4).

26. Valles FE, Perez-Valles CL, Regalado S, Barajas RF, Rubenstein JL, Cha S: Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma. *AJNR American journal of neuroradiology* 2013, **34**(1):35-40.
Usefulness of enhancement-perfusion mismatch in differentiation of CNS lymphomas from other enhancing malignant tumors of the brain. *Quantitative imaging in medicine and surgery* 2017, 7(5):511-519.

28. Nakajima S, Okada T, Yamamoto A, Kanagaki M, Fushimi Y, Okada T, Arakawa Y, Takagi Y, Miyamoto S, Togashi K: *Differentiation between primary central nervous system lymphoma and glioblastoma: a comparative study of parameters derived from dynamic susceptibility contrast-enhanced perfusion-weighted MRI*. *Clinical radiology* 2015, 70(12):1393-1399.

29. Xing Z, You RX, Li J, Liu Y, Cao DR: *Differentiation of primary central nervous system lymphomas from high-grade gliomas by rCBV and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging*. *Clinical neuroradiology* 2014, 24(4):329-336.

30. Toh CH, Wei KC, Chang CN, Ng SH, Wong HF: *Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction*. *AJNR American journal of neuroradiology* 2013, 34(6):1145-1149.

31. Kuppusamy K, Lin W, Cizek GR, Haacke EM: *In vivo regional cerebral blood volume: quantitative assessment with 3D T1-weighted pre- and postcontrast MR imaging*. *Radiology* 1996, 201(1):106-112.

32. Ferreri AJ, Marturano E: *Primary CNS lymphoma*. *Best practice & research Clinical haematology* 2012, 25(1):119-130.

33. Kadoch C, Treseler P, Rubenstein JL: *Molecular pathogenesis of primary central nervous system lymphoma*. *Neurosurgical focus* 2006, 21(5):E1.
34. Soussain C, Hoang-Xuan K, Taillardier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL et al: **Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma**: Societe Francaise de Greffe de Moelle Osseeuse-Therapie Cellulaire. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008, 26(15):2512-2518.

35. Chung SR, Choi YJ, Kim HS, Park JE, Shim WH, Kim SJ: **Tumor Vascular Permeability Pattern Is Associated With Complete Response in Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma**: *Retrospective Cohort Study*. *Medicine* 2016, 95(6):e2624.

36. Jahnke K, Doolittle ND, Muldoon LL, Neuwelt EA: **Implications of the blood-brain barrier in primary central nervous system lymphoma**. *Neurosurgical focus* 2006, 21(5):E11.

Tables

Table 1 The main clinical and cMRI features of three groups of PCNSLs.

|                          | CGM  | WM            | DGM  | \( p \)  |
|--------------------------|------|---------------|------|----------|
| Sex (male/female)        | 15/17| 7/15          | 9/5  | .159     |
| Age (year)               | 56.09±9.8 | 57.96±12.53 | 52.50±13.83 | .393     |
| Contrast-enhancement pattern |     |               |      | .234     |
| Homogeneous              | 29   | 30            | 19   |          |
| Heterogeneous            | 10   | 5             | 2    |          |
| Notch sign               | Yes  | 33            | 31   | 17       | .657     |
| No                       | 6    | 4             | 4    |          |

CGM = cortical gray matter; WM = white matter; DGM = deep gray matter

Table 2 Comparison of DWI and DSC-PWI variables among the three groups of PCNSLs, and DWI variables among the three groups of control group.
|                      | CGM  | WM  | DGM  | $P$  |
|----------------------|------|-----|------|------|
| $\text{ADC}_{\text{min}}$ (10⁻³mm²/s) | 0.61±0.15 | 0.65±0.15 | 0.57±0.14 | 0.169 |
| $\text{ADC}_{\text{mean}}$ (10⁻³mm²/s) | 0.70±0.03 | 0.69±0.03 | 0.69±0.02 | 0.202 |
| $r\text{CBV}_{\text{max}}$ | 2.55±0.64 | 1.34±0.46 | 1.87±0.74 | <0.001 |

CGM = cortical gray matter; WM = white matter; DGM = deep gray matter

**Figures**

![Graph A](image1.png)

**Figure 1**

Comparison of (A) relative maximum cerebral blood volume ($r\text{CBV}_{\text{max}}$) and (B) minimum apparent diffusion coefficient ($\text{ADC}_{\text{min}}$) among PCNSLs of different locations of cortical gray matter (CGM), white matter (WM); deep gray matter (DGM), and (C) mean apparent diffusion coefficient ($\text{ADC}_{\text{mean}}$) among control group of three different locations.
A 52-year-old man with a primary central nervous system lymphoma in the cortical gray matter. a. Axial T2WI demonstrates the heterogeneous high signal intensity on the right temporal lobe. b. Contrast-enhanced axial T1WI demonstrates a lesion enhancement. c. A corresponding ADC map shows the tumor with a decreased ADC value (ADCmin 0.56×10^{-3} mm2/s). The ADCmean value is 0.68×10^{-3} mm2/s in the left normal cortical gray matter. d. A correlative color CBV image shows highly elevated perfusion with the calculated rCBVmax of 3.42.
A 45-year-old woman with PCNSLs in the white matter. a. Axial T2WI shows the homogeneous high signal intensity on the right centrum semiovale. b. Contrast-enhanced axial T1WI demonstrates a lesion enhancement. c. A corresponding ADC map shows the tumor with a decreased ADC value (ADCmin \(0.55 \times 10^{-3} \text{ mm}^2/\text{s}\)). The ADCmean value is \(0.66 \times 10^{-3} \text{ mm}^2/\text{s}\) in the left normal white matter. d. A correlative color CBV image shows slightly elevated perfusion with the calculated rCBVmax of 0.76.
Figure 4

A 72-year-old man with PCNSLs in the deep gray matter. a. Axial T2WI demonstrates homogeneous high signal intensity on the left basal ganglia region. b. Contrast-enhanced axial T1WI demonstrates a lesion enhancement. c. A corresponding ADC map shows the tumor with a decreased ADC value (ADCmin $0.49 \times 10^{-3}$ mm$^2$/s). The ADCmean value is $0.62 \times 10^{-3}$ mm$^2$/s in the right normal deep gray matter. d. A correlative color CBV image shows moderately elevated perfusion with the calculated rCBVmax of 2.10.